Muscle Invasive Bladder Cancer (MIBC) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Muscle Invasive Bladder Cancer (MIBC) – Drugs In Development, 2024 report and make more profitable business decisions.
Muscle invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into the muscle wall of the bladder, making it more likely to spread to other parts of the body. It accounts for about 25% of bladder cancers and has a poor prognosis. The main risk factor for MIBC is smoking, but other factors such as family history, workplace exposure to carcinogens, and prior radiation therapy can also increase the risk. The most common symptom of MIBC is blood in the urine, which can be painless or accompanied by other urinary problems. Diagnosis of MIBC involves urine tests, cystoscopy, biopsy, and imaging tests. Treatment options for MIBC include surgery to remove the bladder or part of it, chemotherapy, radiation therapy, or a combination of these. Early detection and proper management are important for better outcomes.
The Muscle Invasive Bladder Cancer (MIBC) drugs in development market research report provide comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Muscle Invasive Bladder Cancer (MIBC) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 36 molecules, with 34 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Muscle Invasive Bladder Cancer (MIBC) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Muscle Invasive Bladder Cancer (MIBC) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Muscle Invasive Bladder Cancer (MIBC) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Astellas Pharma IncAstraZeneca Plc
Aura Biosciences Inc
BeiGene Ltd
Bristol-Myers Squibb Co
Catalym GmbH
CG Oncology Inc
CHU de Quebec Universite Laval Research Center
Chugai Pharmaceutical Co Ltd
CicloMed LLC
Codiak BioSciences Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Innovent Biologics Inc
Istari Oncology Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Yahong Meditech Co Ltd
Johnson & Johnson
Manhattan Biosolutions Inc
Merck & Co Inc
Merck KGaA
Nanology LLC
Ono Pharmaceutical Co Ltd
Peking University
Pfizer Inc
RemeGen Co Ltd
Shanghai Junshi Biosciences Co Ltd
Sillajen Biotherapeutics
Wuhan Binhui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Muscle Invasive Bladder Cancer (MIBC) reports